Poop pills plus immunotherapy: new hope for colorectal cancer patients?

NCT ID NCT04729322

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot trial tests whether giving fecal microbiota transplants (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help control metastatic colorectal cancer in patients who previously did not respond to immunotherapy alone. The study enrolls 15 adults with mismatch repair deficient (dMMR) tumors. Participants receive antibiotics, then FMT via colonoscopy or capsules, followed by immunotherapy. The goal is to see if changing the gut bacteria can make the cancer respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fecal microbiota transplant (FMT) plus pembrolizumab or nivolumab
What this could lead to
If successful, this approach could help some colorectal cancer patients who didn't respond to immunotherapy alone to control their disease.
What could go wrong
This is a very small pilot study with only 15 participants, so results may not apply broadly. FMT carries risks of infection or side effects, and the combination may still not work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.